Systemic Lupus Erythematosus Leukopak

About Systemic Lupus Erythematosus Leukopak

Systemic Lupus Erythematosus Leukopak for Autoimmunity and Cell Therapy Research

LeukoCore Systemic Lupus Erythematosus Leukopak is collected from donors clinically diagnosed with SLE through IRB-approved apheresis procedures. SLE is a prototypical systemic autoimmune disease: tolerance to nucleic-acid-containing self antigens is lost, autoantibodies form immune complexes, and complement-mediated injury follows across skin, joints, kidney and blood. Each leukopak delivers very large numbers of peripheral blood mononuclear cells from a single characterised donor, making it the right starting material for rare-subset isolation, deep multi-omics and cell-therapy development.

Why a Leukopak for Systemic Lupus Erythematosus

The cell populations that define lupus immunology are rare. A standard blood draw simply does not yield enough plasmacytoid dendritic cells, plasmablasts or low-density granulocytes to interrogate them properly — an apheresis-derived leukopak does.

• Type I interferon axis — SLE is characterised by a well-documented type I interferon signature. Isolating enough plasmacytoid dendritic cells to study TLR7/TLR9 nucleic-acid sensing and interferon production requires leukopak-scale input.
• Autoreactive B-cell compartment — expanded plasmablasts and autoantibody-producing B cells are central to SLE and are the target of approved B-cell-directed therapy; leukopaks provide the numbers needed for sorting, culture and repertoire sequencing.
• CD19-directed cell therapy development — SLE is a leading indication for autologous and allogeneic CAR-T and related approaches. Patient-derived leukopaks support process development, potency assays and T-cell fitness assessment from a genuine lupus starting material.
• Low-density granulocytes and neutrophil extracellular traps — this population, enriched in SLE, co-purifies in the mononuclear fraction and is a recognised source of interferon-inducing nucleic acid.
• Regulatory T-cell and T-cell exhaustion biology — sufficient cells for both phenotyping and functional suppression assays from the same donor and the same collection.
• Longitudinal and multi-assay design — one leukopak can supply flow cytometry, sorted-subset RNA-seq, functional assays and biobanked reserve, eliminating donor-to-donor variance across a study.

Donor Stratification Available

• Disease activity: SLEDAI or physician-assessed activity score where recorded; active flare versus clinical remission
• Autoantibody serology: ANA, anti-dsDNA, anti-Sm/RNP, anti-Ro/SSA and anti-La/SSB status, reported per lot where available
• Complement status: low C3 and/or C4 versus normal complement
• Organ involvement: cutaneous, articular, haematologic, or renal involvement including lupus nephritis
• Treatment status: treatment-naive, hydroxychloroquine, mycophenolate or azathioprine, corticosteroid dose, belimumab, anifrolumab, or B-cell-depleting therapy
• Matched healthy controls available, age- and sex-matched on request

Product Features

• Research Use Only (RUO) human leukopaks
• Clinically confirmed SLE donors
• High cell yield for large-scale studies; yield and viability reported per lot
• Processed and shipped within 24 hours of collection
• Fresh or cryopreserved options available
• IRB-approved and ethically sourced
• Infectious disease testing
• HLA-A typing
• Screen donors with LeukoLot™

De-identified Donor Data

• Verified SLE diagnosis from healthcare providers
• Donor demographics: age, sex assigned at birth, race/ethnicity
• Self-reported medication history and allergies
• Autoantibody serology and complement values where available
• Relevant clinical data and organ involvement history

Applications

• Immune cell characterisation and deep immunophenotyping in SLE
• Rare-subset isolation: plasmacytoid dendritic cells, plasmablasts, regulatory T cells, low-density granulocytes
• Type I interferon and nucleic-acid sensing pathway research
• Autoreactive B-cell and BCR repertoire sequencing
• CD19-directed CAR-T and cell therapy process and potency development
• Cell-based assays, functional suppression assays and cytokine profiling
• Multi-omics studies including single-cell RNA-seq and CITE-seq
• Therapeutic screening and mechanism-of-action research for immunomodulators

Other Systemic Lupus Erythematosus Specimen Types

• Systemic Lupus Erythematosus Serum
• Systemic Lupus Erythematosus Plasma
• Systemic Lupus Erythematosus Whole Blood
• Systemic Lupus Erythematosus PBMC
• Lupus Nephritis Plasma
• Lupus (SLE) Skin Punch Biopsy

Compliance and Quality Assurance

• Collected under IRB oversight with donor e-consent (21 CFR Part 11 compliant)
• HIPAA-compliant handling of donor information
• Rigorous donor screening and documentation

Ordering & Customization

Systemic Lupus Erythematosus Leukopaks are available fresh or cryopreserved. For pricing, availability or a specific stratification request, email learnmore@sanguinebio.com; please also contact us for international shipping or regulatory documentation to confirm regional compliance. Need a different condition, or want to check current availability across our full leukopak inventory? Visit our human leukopak page to browse other disease-state options and live stock status.